Diversification of echinomycin molecular structure by way of chemoenzymatic synthesis and heterologous expression of the engineered echinomycin biosynthetic pathway

Current Opinion in Chemical Biology

Volumn 13, Issue 2, 2009, Pages 189-196

  Watanabe, Kenji ^a   Oguri, Hiroki ^a   Oikawa, Hideaki ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPEPTIDE; ECHINOMYCIN; NATURAL PRODUCT; PEPTIDE LIBRARY; PEPTIDE SYNTHASE; TRIOSTIN A;

ANTINEOPLASTIC ACTIVITY; BACTERIAL GENE; BIOENGINEERING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE CLUSTER; GENETIC ENGINEERING; HETEROLOGOUS EXPRESSION; NONHUMAN; NONRIBOSOMAL PEPTIDE SYNTHESIS; REVIEW;

BIOSYNTHETIC PATHWAYS; ECHINOMYCIN; ESCHERICHIA COLI; GENE EXPRESSION; GENETIC ENGINEERING; PEPTIDE SYNTHASES;

ESCHERICHIA COLI;

EID: 65349153338     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2009.02.012     Document Type: Review

References (30)

1. Bode H.B., and Muller R. The impact of bacterial genomics on natural product research. Angew Chem Int Ed Engl 44 (2005) 6828-6846. A detailed review spotlighting the microbial genome sequences containing biosynthetic gene clusters responsible for important natural products to fully appreciate the molecular diversity of these compounds and viable future directions toward metabolic and biosynthetic engineering to biosynthesize functionally diverse molecules by using molecular biology techniques.
2. Riesenfeld C.S., Schloss P.D., and Handelsman J. Metagenomics: genomic analysis of microbial communities. Annu Rev Genet 38 (2004) 525-552
3. Watanabe K., Praseuth A.P., and Wang C.C.C. A comprehensive and engaging overview of the type III family of polyketide synthases. Curr Opin Chem Biol 11 (2007) 279-286. This review deals with the plant type III polyketide synthases for rational biosynthetic engineering in order to generate molecular diversity and pursue innovative yet biologically potent compounds.
4. Finking R., and Marahiel M.A. Biosynthesis of nonribosomal peptides. Annu Rev Microbiol 58 (2004) 453-488
5. Dawson S., Malkinson J.P., Paumier D., and Searcey M. Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studies. Nat Prod Rep 24 (2007) 109-126
6. Wenzel S.C., and Muller R. Recent developments towards the heterologous expression of complex bacterial natural product biosynthetic pathways. Curr Opin Biotechnol 16 (2005) 594-606. This review provides detailed information on the heterologous production of natural products with an emphasis on polyketides and NRPs by making use of the seemingly endless genetic metagenome resource.
7. Zhang H., Wang Y., and Pfeifer B.A. Bacterial hosts for natural product production. Mol Pharm 5 (2008) 212-225
8. Kealey J.T., Liu L., Santi D.V., Betlach M.C., and Barr P.J. Production of a polyketide natural product in nonpolyketide-producing prokaryotic and eukaryotic hosts. Proc Natl Acad Sci U S A 95 (1998) 505-509
9. Pfeifer B.A., Admiraal S.J., Gramajo H., Cane D.E., and Khosla C. Biosynthesis of complex polyketides in a metabolically engineered strain of E. coli. Science 291 (2001) 1790-1792. This paper reports the feasibility of engineering E. coli to produce complex polyketide natural products. It is the first report in which this class of natural product was produced by means of expressing the biosynthetic gene cluster responsible for synthesizing the macrolactone core structure in a heterologous host, E. coli.
10. Pfeifer B.A., Wang C.C.C., Walsh C.T., and Khosla C. Biosynthesis of yersiniabactin, a complex polyketide-nonribosomal peptide, using Escherichia coli as a heterologous host. Appl Environ Microbiol 69 (2003) 6698-6702
11. Watanabe K., Rude M.A., Walsh C.T., and Khosla C. Engineered biosynthesis of an ansamycin polyketide precursor in Escherichia coli. Proc Natl Acad Sci U S A 100 (2003) 9774-9778. This paper explores the employment of an E. coli-based expression system for the biosynthesis of rifamycin intermediate. According to the authors, a starting unit along with seven genes is required to initiate and complete biosynthesis of the rifamycin intermediate. The polyketide macrosynthetase is described as quadrimodular and was found to be vital for producing the polyketide chain in E. coli. This result supports the possibility for the further genetic manipulation of complex natural products with unprecedented power.
12. Gruenewald S., Mootz H.D., Stehmeier P., and Stachelhaus T. In vivo production of artificial nonribosomal peptide products in the heterologous host Escherichia coli. Appl Environ Microbiol 70 (2004) 3282-3291
13. Peiru S., Menzella H.G., Rodriguez E., Carney J., and Gramajo H. Production of the potent antibacterial polyketide erythromycin C in Escherichia coli. Appl Environ Microbiol 71 (2005) 2539-2547
14. Watanabe K., Hotta K., Praseuth A.P., Koketsu K., Migita A., Boddy C.N., Wang C.C.C., Oguri H., and Oikawa H. Total biosynthesis of antitumor nonribosomal peptides in Escherichia coli. Nat Chem Biol 2 (2006) 423-428. In this article, authors describe unprecedented de novo biosynthesis of biologically active forms of NRPs using a heterologous host, E. coli. The system can serve not only as an effective and flexible platform for the large-scale preparation of natural products from simple carbon and nitrogen sources, but also as a general tool for the detailed characterizations and rapid engineering of biosynthetic pathways for the microbial syntheses of novel compounds and their analogs.
15. Praseuth A.P., Praseuth M.B., Oguri H., Oikawa H., Watanabe K., and Wang C.C.C. Improved production of triostin A in engineered Escherichia coli with furnished quinoxaline chromophore by design of experiments in small-scale culture. Biotechnol Prog 24 (2008) 134-139
16. Koketsu K., Oguri H., Watanabe K., and Oikawa H. Enzymatic macrolactonizations in the presence of DNA leading to triostin A analogs. Chem Biol 15 (2008) 818-828. This paper provides an additional insight into the mechanism of echinomycin TE domain and chemoenzymatic synthesis of the bis-intercalator antibiotics. This chemoenzymatic strategy affords the potential of inducing a divergence of cyclic peptide scaffolds.
17. Takahashi K., Koshino H., Esumi Y., Tsuda E., and Kurosawa K. SW-163C and E, novel antitumor depsipeptides produced by Streptomyces sp. II. Structure elucidation. J Antibiot (Tokyo) 54 (2001) 622-627
18. This article describes successful engineering of the E. coli echinomycin biosynthetic pathway for the production of a synthetic analog TANDEM by site-specific mutagenesis of an echinomycin biosynthetic gene, and a novel bioactive compound by the introduction of a gene from the newly identified SW-163 biosynthetic gene cluster.
19. Trauger J.W., Kohli R.M., Mootz H.D., Marahiel M.A., and Walsh C.T. Peptide cyclization catalysed by the thioesterase domain of tyrocidine synthetase. Nature 407 (2000) 215-218. This paper discusses the tyrocidine synthetase TE domain and its ability to cyclize and release a broad range of new substrates and products by means of engineering its enzymatic assembly lines.
20. Hoyer K.H., Mahlert C., and Marahiel M.A. The iterative gramicidin S thioesterase catalyzes peptide ligation and cyclization. Chem Biol 14 (2007) 13-22. In this work, the investigators characterized the iterative TE domain and proposed its value as a tool for combinatorial biosynthesis leading to the synthesis of new bioactive molecules.
21. ••].
22. ••] reports an elucidated crystal structure of TE domains that were integrated into discrete NRPSs. These observations provide a clearer picture of the role that TE domains play and the mechanism employed during chain-termination. This is the first reported crystal structure of TE domain modulated in NRPS.
23. Mahlert C., Sieber S.A., Grünewald J., and Marahiel M.A. Chemoenzymatic approach to enantiopure streptogramin B variants: characterization of stereoselective pristinamycin I cyclase from Streptomyces pristinaespiralis. J Am Chem Soc 127 (2005) 9571-9580
24. Wagner B., Schumann D., Linne U., Koert U., and Marahiel M.A. Rational design of bacitracin A derivatives by incorporating natural product derived heterocycles. J Am Chem Soc 128 (2006) 10513-10520
25. Low C.M.L., Olsen R.K., and Waring M.J. Sequence preferences in the binding to DNA of triostin A and TANDEM as reported by DNase I footprinting. FEBS Lett 176 (1984) 414-420
26. Fox K.R., Olsen R.K., and Waring M.J. Equilibrium and kinetic studies on the binding of des-N-tetramethyltriostin A to DNA. Biochim Biophys Acta 696 (1982) 315-322
27. Lee J.S., and Waring M.J. Interaction between synthetic analogues of quinoxaline antibiotics and nucleic acids. Changes in mechanism and specificity related to structural alterations. Biochem J 173 (1978) 129-144
28. Vevodova J., Graham R.M., Raux E., Schubert H.L., Roper D.I., Brindley A.A., Scott A.I., Roessner C.A., Stamford N.P.J., Stroupe M.E., et al. Structure/function studies on a S-adenosyl-l-methionine-dependent uroporphyrinogen III C methyltransferase (SUMT), a key regulatory enzyme of tetrapyrrole biosynthesis. J Mol Biol 344 (2004) 419-433
29. Nakaya M., Oguri H., Takahashi K., Fukushi E., Watanabe K., and Oikawa H. Relative and absolute configuration of antitumor agent SW-163D. Biosci Biotechnol Biochem 71 (2007) 2969-2977
30. Fischbach M.A., Lai J.R., Roche E.D., Walsh C.T., and Liu D.R. Directed evolution can rapidly improve the activity of chimeric assembly-line enzymes. Proc Natl Acad Sci U S A 104 (2007) 11951-11956. This paper describes approaches to improve the activity of impaired chimeric NRPSs through domain swapping. Some of these assembly lines were functionally restored with both enzyme activity and product yield by way of directed evolution.